Current Edition

PCI Announces Appointment to its Manufacturing Business Development Team

Leading pharmaceutical outsourcing services provider PCI Pharma Services has announced the appointment of Jennifer Goldberg to its Manufacturing Business Development team.
Jennifer joins PCI as Senior Account Executive, with responsibility for developing opportunities and building sales in PCI’s US West Coast territory to ensure continued growth and success in this key market.  Jennifer has an extensive background in drug development and manufacturing, with varying roles in business development at leading CMOs over a successful 20-year career.
Commenting on Jennifer’s appointment, Rob Jones, Business Development Director International at PCI, said: “We are delighted to welcome Jennifer to PCI.  She brings a tremendous amount of knowledge, experience and credibility to our business.  We look forward to her valuable contributions to the organization and in providing our customers the industry leading experience.”
Jennifer said of her new role: “I’m excited to join PCI Pharma Services and apply my previous experience to my new position. I have a long history of working in sales and business development in this space.  I am looking forward to using my knowledge to help clients overcome their difficult drug development challenges and realize successful commercialization of their lifesaving medicines.”
PCI recently announced the investment in a fully contained Xcelodose® 600S unit in support of drug development for highly potent molecules.  The technology allows for drug-in-capsule delivery in early phase clinical trials allows clients to realize significant reductions in development timelines as well as reduce costs by minimizing formulation development activity and reducing use of costly API.  The Xcelodose® 600S technology is enhanced by a PCI-designed, custom-built XceloprotectTM containment system providing an early stage development solution for the management of highly potent molecules.
The company also recently announced acquisition of Millmount Healthcare, expanding its presence into Ireland and the European Union, adding four facilities in the greater Dublin area.